• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.66% Nasdaq Up0.88%

    More On B8F.DE



    News & Info


    Analyst Coverage

    • Analyst Opinion
    • Analyst Estimates


    • Major Holders
    • Insider Transactions
    • Insider Roster


    Biofrontera AG (B8F.DE)

    3.19 Up 0.02(0.66%) 11:36AM EDT
    ProfileGet Profile for:
    Biofrontera AG
    Hemmelrather Weg 201
    Leverkusen, 51377
    Germany - Map
    Phone: 49 214 87 63 20
    Fax: 49 214 87 63 290
    Website: http://www.biofrontera.com

    Index Membership:N/A
    Full Time Employees:55

    Business Summary 

    Biofrontera AG, a biopharmaceutical company, primarily focuses on the discovery, development, and distribution of dermatological drugs and dermatological-tested cosmetics for the treatment and care of diseased skin. The company’s products include Ameluz, a prescription drug for the treatment of actinic keratosis, a superficial skin cancer; BF-RhodoLED, a lamp for photodynamic therapy with LEDs emitting red light at an average wavelength of 635 nm; Belixos, a cream with herbal ingredients for the care of inflamed, itchy, and flaky skin, such as localized itching, atopic dermatitis, or psoriasis; Belixos LIQUID to treat itching and scaliness, and restore the scalp’s natural balance; Belixos GEL for use on inflamed and reddened skin, and skin prone to impurities; and Belixos PROTECT for the needs of sun-damaged skin. It is also developing BF-derm1, which is in Phase II clinical trial for the treatment of chronic and antihistamine-refractory urticaria; and BF-1, a serotonin receptor antagonist that is in Phase I clinical trial to treat migraine prophylaxis. The company was founded in 1997 and is headquartered in Leverkusen, Germany.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Biofrontera AG

    Key Executives 
    Prof. Hermann Lübbert Ph.D., 60
    Co-Founder, Chairman of Management Board and Chief Exec. Officer
    Mr. Thomas Schaffer ,
    Chief Financial Officer and Member of Management Board
    Mr. Christoph Dünwald , 48
    Chief Commercial Officer, Head of Sales & Marketing and Additional Member of Management Board
    Ms. Monica Tamborini , 60
    Chief Exec. Officer of Biofrontera - US Operations
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in EUR.